Ribeiro, Gabriel H.; Guedes, Adriana P. M.; de Oliveira, Tamires D.; de Correia, Camila R. S. T. b.; Colina-Vegas, Legna; Lima, Mauro A.; Nobrega, Joaquim A.; Cominetti, Marcia R.; Rocha, Fillipe V.; Ferreira, Antonio G.; Castellano, Eduardo E.; Teixeira, Felipe R.; Batista, Alzir A. published the artcile< Ruthenium(II) Phosphine/Mercapto Complexes: Their in Vitro Cytotoxicity Evaluation and Actions as Inhibitors of Topoisomerase and Proteasome Acting as Possible Triggers of Cell Death Induction>, Application In Synthesis of 96-53-7, the main research area is preparation ruthenium diphenylphosphinobutane phosphine diphenylpyridylphosphine thiazolinethiol complex; crystal structure ruthenium diphenylphosphinobutane phosphine diphenylpyridylphosphine thiazolinethiol complex; HSA interaction ruthenium diphenylphosphinobutane phosphine diphenylpyridylphosphine thiazolinethiol complex; cyclic voltammetry ruthenium diphenylphosphinobutane phosphine diphenylpyridylphosphine thiazolinethiol complex; DNA interaction ruthenium diphenylphosphinobutane phosphine diphenylpyridylphosphine thiazolinethiol complex; anticancer activity ruthenium diphenylphosphinobutane phosphine diphenylpyridylphosphine thiazolinethiol complex.
A series of new ruthenium complexes of the general formula [Ru(NS)(dpphpy)(dppb)]PF6 (Ru1-Ru3), where dpphpy = diphenyl-2-pyridylphosphine, NS ligands = 2-thiazoline-2-thiol (tzdt, Ru1, 1), 2-mercaptopyrimidine (pySm, Ru2, 2), and 4,6-diamino-2-mercaptopyrimidine (damp, Ru3, 3), and dppb = 1,4-bis(diphenylphosphino)butane, were synthesized and characterized by elemental anal., spectroscopic techniques (IR, UV/visible, and 1D and 2D NMR), and x-ray diffraction. In the characterization, the correlation between the phosphorus atoms and their resp. aromatic hydrogen atoms of the compounds in the assignment stands outs, by 1H-31P HMBC experiments The compounds show anticancer activities against A549 (lung) and MDA-MB-231 (breast) cancer cell lines, higher than the clin. drug cisplatin. All of the complexes are more cytotoxic against the cancer cell lines than against the MRC-5 (lung) and MCF-10 Å (breast) nontumorigenic human cell lines. For A549 tumor cells, cell cycle anal. upon treatment with Ru2 showed that it inhibits the mitotic phase because arrest was observed in the Sub-G1 phase. Addnl., the compound induces cell death by an apoptotic pathway in a dose-dependent manner, according to annexin V-PE assay. The multitargeted character of the compounds was studied, and the biomols. were DNA, topoisomerase IB, and proteasome, as well as the fundamental biomol. in the pharmacokinetics of drugs, human serum albumin. The complexes do not target DNA in the cells. At low concentrations, the compounds showed the ability to partially inhibit the catalytic activity of topoisomerase IB in the process of relaxation of the DNA plasmid. Among the complexes assayed in cultured cells, complex Ru3 was able to diminish the proteasomal chymotrypsin-like activity to a greater extent. New ruthenium phosphine complexes show anticancer activities against A549 (lung) and MDA-MB-231 (breast) cancer cell lines, higher than the clin. drug cisplatin. For A549 tumor cells, cell cycle anal. upon treatment with Ru2 showed that it inhibits the mitotic phase because arrest was observed in the Sub-G1 phase and induces cell death by an apoptotic pathway. The multitargeted character of the compounds was studied with the biomols. DNA, topoisomerase IB, and proteasome.
Inorganic Chemistry published new progress about Antitumor agents. 96-53-7 belongs to class thiazole, and the molecular formula is C3H5NS2, Application In Synthesis of 96-53-7.
Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica